SCHEMBL25458682

SCHEMBL25458682

C=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@H](O)C1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDA P32320 8/20 0.42
▸ SLC28A1 O00337 1/20 0.42
▸ SLC28A2 O43868 1/20 0.42
▸ SLC29A1 Q99808 1/20 0.42
▸ SLC28A3 Q9HAS3 1/20 0.42
▸ GMNN O75496 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ DNMT1 P26358 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ MTOR P42345 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ HBB P68871 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ PYGM P11217 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18016507 0.89 ADORA3 (0.36) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL18016510 0.89 CHEK1 (0.34) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL20750703 0.87 DYRK1A (0.36) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16478470 0.85 LMNA (0.43) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL17732554 0.85 CDA (0.42) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL14928661 0.83 P2RY2 (0.36) —
SCHEMBL17463479 0.83 P2RY2 (0.36) —
SCHEMBL15249018 0.83 P2RY2 (0.36) —
SCHEMBL14945957 0.83 P2RY2 (0.36) —
SCHEMBL18118099 0.83 P2RY2 (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399403-A1 MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE BioNTech SE (DE) 2023-12-14 — — US disclosed
US-20230338512-A1 CORONAVIRUS VACCINE BioNTech SE (DE) 2023-10-26 — — US disclosed
US-11779659-B2 RNA constructs and uses thereof BioNTech SE (DE) 2023-10-10 — — US disclosed
US-20230287088-A1 BINDING AGENTS FOR CORONAVIRUS S PROTEIN BioNTech SE (DE) 2023-09-14 — — US disclosed
US-20230145774-A1 TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH (DE) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11779659-B2 RNA constructs and uses thereof RNGTT, RNMT, NSUN3 CDA 630/4885SLC28A1 1543/4885SLC28A2 1514/4885
US-20230145774-A1 TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION ICOS, STING1, EIF2AK2 CDA 584/4885SLC28A1 2536/4885SLC28A2 2766/4885
US-20230399403-A1 MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE PDCD1, CD274, PDCD1LG2 CDA 45/4885SLC28A1 1917/4885SLC28A2 2503/4885
US-20230287088-A1 BINDING AGENTS FOR CORONAVIRUS S PROTEIN SARS1, CD2BP2, RBM3 CDA 996/4885SLC28A1 1426/4885SLC28A2 1521/4885
US-20230338512-A1 CORONAVIRUS VACCINE SARS1, CD4, ACE2 CDA 1165/4885SLC28A1 4459/4885SLC28A2 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback